Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up

Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17.

Authors

Anne M Horne¹, Borislav Mihov¹, Ian R Reid^{2

3}

Affiliations

¹ Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand.
² Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand. i.reid@auckland.ac.nz.
³ Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand. i.reid@auckland.ac.nz.

PMID: 31087124
DOI: 10.1007/s00223-019-00553-w

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / pharmacology*
Bone Density / drug effects*
Bone Density Conservation Agents / pharmacology
Bone Diseases, Metabolic / drug therapy*
Denosumab / pharmacology*
Follow-Up Studies
Humans
Zoledronic Acid / pharmacology*

Substances

Antibodies, Monoclonal
Bone Density Conservation Agents
romosozumab
Denosumab
Zoledronic Acid